ImCyse S.A.

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning

The positive Phase III results and subsequent US approval of lecanemab for Alzheimer’s disease was reflected by a spike in enthusiasm for the central nervous system (CNS) space among the 90 or so resp

Halfway through February, seven different sources of funding for health care and life science innovations have announced newly raised pools of cash totaling $2.2bn for a wide array of technologies, in

Pfizer Inc. is to acquire a stake in ImCyse S.A. having entered into a collaboration to develop treatments for rheumatoid arthritis using the Belgian biotech's technology to produce modified peptid